India, Aug. 1 -- Shares of 4D Molecular Therapeutics (FDMT) are up over 26% to $5.69 in premarket trading Friday, following positive 60-week data from its Phase II SPECTRA trial.
The SPECTRA trial is evaluating the company's lead gene therapy candidate, 4D-150, in diabetic macular edema.
DME, or diabetic macular edema, is a complication of diabetic retinopathy and is characterized by inflammation and swelling in the macula due to leakage from blood vessels, which can lead to vision loss.
According to the results announced today, 4D-150 continues to be well tolerated, with no intraocular inflammation reported at any dose level or timepoint. Moreover, the therapy demonstrated durable, dose-dependent efficacy, with sustained improvements in...